Cyclooxygenase-2 expression in pediatric sarcomas

Pediatric and Developmental Pathology

Volumn 5, Issue 4, 2002, Pages 356-364

  Dickens, David S ^a   Kozielski, Rafal ^a   Khan, Javed ^b   Forus, Anne ^c   Cripe, Timothy P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cyclooxygenase 2; Ewing sarcoma; Osteosarcoma; Rhabdomyosarcoma

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER STAGING; CHILD; DNA MICROARRAY; EWING SARCOMA; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR CLASSIFICATION; TUMOR GROWTH;

ADOLESCENT; BONE NEOPLASMS; CHILD; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RHABDOMYOSARCOMA; SARCOMA; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 0036655707     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10024-002-0005-1     Document Type: Article

References (45)

1. Robinson LL. General principles of the epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, third ed. Philadelphia: Lippincott-Raven, 1997;1-10.
2. Shah S, Weitman S, Langevin AM, et al. Phase I therapy trials in children with cancer. J Pediatr Hematol Oncol 1998;20:431-438.
3. Packer RJ. Brain tumors in children. Arch Neurol 1999;56: 421-425.
4. Chen AR. High-dose therapy with stem cell rescue for pediatric solid tumors: rationale and results. Pediatr Transplant 1999;3:Suppl 1:78-86.
5. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999;4:34-44.
6. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
7. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352.
8. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
9. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916.
10. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325-1329.
11. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-1596.
12. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
13. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89: 589-596.
14. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011.
15. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60:4926-4931.
16. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338.
17. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61:303-308.
18. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-434.
19. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103.
20. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:6 Pt 1:G1061-G1067.
21. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772.
22. Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001;61:1451-1456.
23. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
24. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-5602.
25. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-2430.
26. Komhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000;157:29-35.
27. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-671.
28. Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000;165:2719-2728.
29. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-140.
30. Munstedt K, Steen J, Knauf AG, et al. Steroid hormone receptors and long-term survival in invasive ovarian cancer. Cancer 2000;89:1783-1791.
31. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-4068.
32. Kahlos K, Soini Y, Sormunen R, et al. Expression and prognostic significance of catalase in malignant mesothelioma. Cancer 2001;91:1349-1357.
33. Wong SC, Chan JK, Lee KC, et al. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 2001;194: 35-42.
34. Brabletz T, Herrmann K, Jung A, et al. Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 2000;156:865-870.
35. Krajewska M, Krajewska S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
36. Khan J, Wei JS, Ringner M. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-679.
37. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer. Cell 1998;93: 705-716.
38. Paik JH, Ju JH, Lee JY, et al. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem 2000;275:28173-28179.
39. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-4637.
40. Elder DJ, Halton DE, Crew TE, et al. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553-560.
41. Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-649.
42. Williams CS, Smalley W, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-6051.
43. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418.
44. Shono T, Tofilon TJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61:4375-4381.
45. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.